Trial intelligence / Profile preview

OPTIC RCC

NCT05361720Phase 2Recruiting

Sponsor: Vanderbilt-Ingram Cancer Center
Start: Dec 2022
Primary completion: Oct 2027
Countries: 1

Overview

Phase 2, open-label trial of ipilimumab, nivolumab and cabozantinib in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Overall Response Rate at 4 years. Started Dec 2022; status: recruiting.

Drugs

ipilimumabnivolumabcabozantinib

Conditions

clear cell renal cell carcinoma (ccRCC)

Beyond the preview

Go deeper on NCT05361720.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT05361720.